Today: 30 June 2026
Browse Category

Pharmaceuticals 16 June 2026 - 30 June 2026

Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus

Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus

Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%. It’s really about scale for investors. Reuters said sales of GLP-1 drugs on Alibaba and JD.com sites hit around 1.4 billion yuan in Q1, using Jefferies numbers. That would be about $828 million a year through those e-commerce channels. Meanwhile, Pfizer’s annualized dividend payout based on $0.43 per share and 5.731 billion Q1 diluted shares comes to almost $9.9 billion.
30 June 2026
··
Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus

Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus

Universe Pharmaceuticals INC shares surged in late Monday trading on a new patent deal, but what stood out for investors was the big share count jump. The China-based specialty pharma said it would issue 4,376,552 Class A shares to Best Praise International. StockAnalysis listed just 651,310 shares outstanding toward session end. The regular Nasdaq session closed at the dateline. The exchange’s regular hours are 9:30 a.m. to 4 p.m. ET, with after-hours from 4 p.m. to 8 p.m. Nasdaq’s 2026 holiday calendar puts the next U.S. equity market closure on July 3 for Independence Day, not June 29.
29 June 2026
···
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review

Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review

Moderna, Inc. heads into Monday’s U.S. session with its shares now outpacing most analyst targets, leaving the main story a stock issue instead of a scientific one. The stock traded at $67.63 in premarket at 7:01 a.m. EDT, up 0.54%, after jumping 12.59% to $67.27 on Friday. Volume hit 14.46 million shares Friday, 203% of the 65-day average. Moderna was one of the few large healthcare plays to rally Friday, as the rest of the market drifted lower. The S&P 500 slipped 0.05% and the Nasdaq lost 0.24%, according to Reuters, but Moderna shares shot up nearly 13% after its investor event. Early Monday, U.S. futures traded stronger, with S&P 500 E-minis up 0.68% and Nasdaq 100 E-minis up 1.02% at 5:00 a.m. ET.
29 June 2026
···
Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop

Eli Lilly and Company (NYSE:LLY) stock nears Cantor target after $76 billion Friday pop

At 05:01 EDT, the New York Stock Exchange cash session had not opened. NYSE lists a 9:30 a.m. to 4:00 p.m. ET core session, and its 2026 holiday list shows the next full U.S. market closure is July 3 for Independence Day observed. Eli Lilly and Company starts the week with a cleaner investor problem than most mega-cap drug stocks: the stock has already priced in a lot of good news. Friday’s 7.13% jump pushed Lilly to a record close of $1,208.12, and a 4:46 a.m. EDT pre-market quote showed the shares up another 1.69% at $1,228.52. WSJ data put Friday volume at 7.72 million shares, against a 65-day average of 3.25 million.
29 June 2026
··
Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land

Eli Lilly (NYSE:LLY) gains $76 billion in one day as Jaypirca headlines land

Eli Lilly and Company closed at $1,208.12 on Friday, up $80.43. Markets in U.S. cash equities were closed Saturday, leaving Friday as the last pricing. About 7.73 million shares traded, coming in at roughly 2.5 times the average volume listed on Google Finance. Lilly’s blood-cancer drug didn’t just get a $76 billion re-rating overnight. What buyers paid for is the bigger Lilly trade—European oncology news, Medicare obesity coverage just ahead, and a health-care move while tech stumbled.
27 June 2026
··
Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly (NYSE:LLY) move lifts healthcare ETF on Medicare GLP-1 signal

Eli Lilly and Company jumped 6.5% to $1,200.98 by 1:46 p.m. EDT Friday, tacking on about $65.7 billion in market cap. Shares hovered close to the session’s high of $1,208.18. The stock was at 42.7 times earnings, with 3.6 million shares traded. The index math told more of the story. Lilly made up 15.84% of the Health Care Select Sector SPDR Fund as of June 25, State Street said. Based on that, Lilly’s move on Friday added about 1.03 percentage points to XLV—roughly 43% of the ETF’s 2.4% rise at one point.
26 June 2026
···
Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x

Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x

Shuttle Pharmaceuticals Holdings Inc surged Friday as United Dogecoin, its unit, said it picked up its first Dogecoin miners and locked in a hydroelectric data centre site. The former drug developer saw sharp trading and became one of the busiest micro-cap names of the session. The stock jumped 27.38% to $4.815 as of 11:02 a.m. EDT, trading between $4.56 and $6.15. Volume was 21.7 million shares, far above the 65-day average of 311,064, Wall Street Journal data showed. The Health Care/Life Sciences group added 1.09%. The Russell 2000 slipped 0.10%.
26 June 2026
···
Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed

Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed

Pfizer Inc. opens Thursday carrying a clearer income pitch, but growth looks shaky. Shares have slid, sending the dividend yield above 7%. The company scored an FDA win for Ibrance, its established breast cancer drug. But sigvotatug vedotin, a lung cancer antibody-drug conjugate from the Seagen deal, failed in late-stage testing. U.S. markets weren’t open yet in New York. NYSE starts core trading at 9:30 a.m. ET until 4 p.m. ET, and June 25 isn’t listed as a 2026 holiday on the exchange. Pfizer last traded at $24.09 in premarket at 08:53 EDT, compared to Wednesday’s close of $24.04.
25 June 2026
·
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk (CPH:NOVO-B) gains as South Africa copycat order tops Ozempic, Wegovy local sales

Novo Nordisk’s B shares jumped 2.6% to 307.75 Danish crowns on Tuesday. The stock is up 5.1% since Friday’s close and has gained 9.9% over three sessions. The OMXC25 index in Copenhagen fell 0.07%. Novo put a new number out for investors: 84,500. That’s roughly how many compounded semaglutide units iDexis supplied each month in South Africa, the company told a court. Novo says that’s more than it sold of Ozempic and Wegovy combined in the country. A court order on Monday barred iDexis from compounding, supplying, and marketing the semaglutide products while they’re under regulatory review. Compounding in this case refers to pharmacies preparing or adjusting a drug for patients. The court filing doesn’t clarify if a unit from iDexis matches a Novo pack, so there’s no way to turn the number into revenue.
24 June 2026
····
Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal

Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal

Pfizer Inc. shares fell on Tuesday. The company said a key lung cancer drug from its Seagen unit didn’t hit the main endpoint in a late-stage study. That’s another setback for Pfizer as it tries to spark growth again after its COVID-era products. Pfizer shares slipped 0.8% to $24.89 in afternoon trading. The Health Care Select Sector SPDR ETF gained 1.3%. The SPDR S&P 500 ETF Trust dropped roughly 1%, and Pfizer lagged the health-care sector as the wider market also fell. Merck, which will have its Keytruda in Pfizer’s next trial of the drug, rose 2.9%.
23 June 2026
··
AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie said Monday it will buy Apogee Therapeutics for $10.9 billion in cash, picking up a late-stage eczema drug in what would be its biggest deal in over five years. The $135.11 per share offer is about 49% over Apogee’s June 18 close. Both companies’ boards signed off, aiming to wrap up the deal in the third quarter. AbbVie is buying Apogee as it’s still working to replace Humira sales lost to biosimilar rivals and getting ready for the patent cliffs looming on Skyrizi and Rinvoq. Immunology brought in more than $30 billion for AbbVie in 2025, but Humira sales dropped 49%. CEO Robert Michael called the deal an “excellent fit.” J.P. Morgan analyst Chris Schott cited appetite for late-stage growth assets. RBC’s Brian Abrahams said AbbVie is “an ideal acquirer.”
22 June 2026
···
AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie moves to acquire Apogee in $10.9 billion bet on immunology

AbbVie said Monday it’s buying Apogee Therapeutics for $10.9 billion in cash, making this its largest deal since 2019. The company is looking to strengthen its immunology pipeline with Apogee’s long-acting immune-disease drugs. AbbVie and Apogee put out a joint release on the agreement, according to a securities filing. They expect the deal to close in the third quarter of 2026. It’s not a coincidence. Big pharma is stepping up biotech deals as expiring patents hit old blockbuster drugs, with over $200 billion in healthcare M&A announced this year, according to LSEG figures reported by the Financial Times.
22 June 2026
··
Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands

Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands

Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend. Dave Denton has been a key figure pitching Pfizer’s post-COVID plan to Wall Street—cutting costs after weaker pandemic sales, adding big deals, and leaning on a pipeline with unproven strength. Pfizer said Denton will leave Aug. 15. Cecile Guegan steps in as interim CFO the next day while Pfizer looks inside and outside for a replacement. CEO Albert Bourla called Denton a “steady and trusted steward.” Denton said Pfizer is “in excellent hands.”
21 June 2026
··
Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dip after CFO departure raises new questions about 2026 outlook

Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth. That’s what investors head into next week with. Pfizer isn’t only swapping finance chiefs; the company is making the change as it works to prove its deals, cuts, and fresh drugs are enough to offset weaker COVID vaccine and antiviral demand.
19 June 2026
··
Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan

Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild. The shares were down 83 cents, or about 3.2%, at $25.09 around 11:42 a.m. EDT. That compared with a roughly 0.6% rise in the SPDR S&P 500 ETF Trust, a widely used tracker of the S&P 500 index.
18 June 2026
··
Pfizer trades up with Rigel’s Veppanu deal done

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed. Dow sets a record, Pfizer edges higher as tech lags Pfizer finished at $26.04, up 0.15%. The S&P 500 slipped 0.57% and the Nasdaq lost 1.15%. The Dow gained 0.64% for a record close, lifted as money rotated out of tech stocks into other sectors.
17 June 2026
·····
AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression

AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression

AtaiBeckley Inc. jumped 7.8% to $4.14 on Tuesday. Chief Executive Srinivas Rao said the company’s lead depression drug, BPL-003, advanced into Phase 3 trials. ATAI shares on Nasdaq moved between $3.83 and $4.34. Volume was close to 10 million shares. This is important as the company has moved from the planning stage to executing on its core asset. Phase 3 is the late-stage human trial, often the final hurdle for approval if the results hold up.
16 June 2026
·
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms

Outlook Therapeutics, Inc. stock surged Tuesday after the company said the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application, or BLA, for ONS-5010/LYTENAVA as a treatment for wet age-related macular degeneration. A BLA is the FDA application used to seek approval to market a biologic medicine. OTLK traded at $1.51, up about 30.2% from its previous close of $1.16, with intraday volume above 33.7 million shares, according to market data available in afternoon trading. The move was driven by a clearer and faster regulatory timeline. Outlook said the FDA classified the resubmission as a Class 1 review and set a Prescription Drug User Fee Act, or PDUFA, target action date of July 29, 2026. The PDUFA date is the FDA’s goal date to act on an application, not a guarantee of approval. Chief Executive Bob Jahr said the company was “very pleased” that the FDA accepted the application and called it “great news for Outlook and the LYTENAVA™ team, patients and the retina community.”
16 June 2026
··
CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Inc. shares spiked in premarket trading Tuesday, quoted around $3.30 after closing at $2.48 on Monday. The stock was up more than 30%, with MarketScreener and MT Newswires tying the jump to an SEC filing late Monday. The pop wasn’t about new clinical news. Instead, it followed a show of insider confidence: a Form 4 showed the Joshua S. Boger 2021 Trust bought 955,414 units at $3.14 apiece in a private placement, totaling about $3 million. Private placements are limited sales to select investors, not the public. That difference is important. The deal wasn’t an open-market buy, but traders watched it since the units priced above Monday’s close and came from a trust linked to Joshua S. Boger, who chairs CervoMed’s board and owns 10%. Each unit had a common share and Series B and C warrants—let holders buy stock later at fixed prices. Series B warrants have a $3.32 exercise price and expire in 2031; Series C warrants, $3.14, expire in 2027, per the SEC Form 4. Warrants can help finance a deal but may dilute holders if exercised.
16 June 2026
··
1 2 3 … 42

Stock Market Today

  • Electro Optic Systems (ASX:EOS) jumps 5.6% on S&P/ASX 200 move, outlook mixed
    June 30, 2026, 6:57 AM EDT. Shares in Electro Optic Systems Holdings (ASX: EOS) rose 5.6% after the stock was added to both the S&P/ASX 200 and Industrials Sector indices, raising its profile and boosting liquidity. The news could pull in flows from index funds and more institutional money. EOS makes counter drone, laser, and space control tech, aiming to turn defense deals into steady revenue. A recent €10 million investment in a European AI-based drone defense hub fits this plan. Still, the company faces recurring risks around its heavy dependence on big defense contracts and swings in financials. Market forecasts point to A$514.7 million revenue and A$62.6 million earnings by 2029, with some analysts seeing about 26% upside to fair value near A$12.94. But analyst views are split, and the outlook remains unsettled as the story develops.
Go toTop